MX369201B - Formulación líquida de un conjugado de insulina de acción prolongada. - Google Patents
Formulación líquida de un conjugado de insulina de acción prolongada.Info
- Publication number
- MX369201B MX369201B MX2015000988A MX2015000988A MX369201B MX 369201 B MX369201 B MX 369201B MX 2015000988 A MX2015000988 A MX 2015000988A MX 2015000988 A MX2015000988 A MX 2015000988A MX 369201 B MX369201 B MX 369201B
- Authority
- MX
- Mexico
- Prior art keywords
- long
- insulin conjugate
- liquid formulation
- acting insulin
- formulation
- Prior art date
Links
- 102000016261 Long-Acting Insulin Human genes 0.000 title abstract 3
- 108010092217 Long-Acting Insulin Proteins 0.000 title abstract 3
- 229940100066 Long-acting insulin Drugs 0.000 title abstract 3
- 239000012669 liquid formulation Substances 0.000 title abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 1
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- 231100001261 hazardous Toxicity 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000007951 isotonicity adjuster Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a una formulación líquida de un conjugado de insulina de acción prolongada que comprende una cantidad farmacéuticamente eficaz de un conjugado de insulina de acción prolongada, en el cual un péptido fisiológicamente activo, que es una insulina, se encuentra unido a la región Fc de una inmunoglobulina, y comprende además un estabilizante libre de albúmina que comprende una solución amortiguadora, un alcohol de azúcar, un tensioactivo no iónico, y un agente isotónico. Método para preparar la formulación. Además, para impedir la contaminación microbiana en múltiples usos, se puede agregar un conservante a la formulación. La formulación líquida de la presente invención no comprende una albúmina de suero humano y factores potencialmente peligrosos para el cuerpo, y por lo tanto tiene excelente estabilidad durante el almacenamiento del conjugado de insulina sin presentar riesgos de infección viral.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120081477 | 2012-07-25 | ||
PCT/KR2013/006673 WO2014017847A1 (en) | 2012-07-25 | 2013-07-25 | A liquid formulation of long-acting insulin conjugate |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015000988A MX2015000988A (es) | 2015-11-13 |
MX369201B true MX369201B (es) | 2019-10-30 |
Family
ID=49997581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015000988A MX369201B (es) | 2012-07-25 | 2013-07-25 | Formulación líquida de un conjugado de insulina de acción prolongada. |
Country Status (21)
Country | Link |
---|---|
US (1) | US10987424B2 (es) |
EP (1) | EP2877157B1 (es) |
JP (2) | JP6385925B2 (es) |
KR (1) | KR102088856B1 (es) |
CN (1) | CN104519871B (es) |
AR (1) | AR091902A1 (es) |
AU (1) | AU2013293718B2 (es) |
BR (1) | BR112015001457B1 (es) |
CA (1) | CA2879976C (es) |
CY (1) | CY1121356T1 (es) |
DK (1) | DK2877157T3 (es) |
ES (1) | ES2715326T3 (es) |
HK (1) | HK1207816A1 (es) |
HU (1) | HUE042246T2 (es) |
MX (1) | MX369201B (es) |
PL (1) | PL2877157T3 (es) |
PT (1) | PT2877157T (es) |
RU (1) | RU2670270C2 (es) |
TR (1) | TR201903661T4 (es) |
TW (2) | TWI605824B (es) |
WO (1) | WO2014017847A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9180261B2 (en) | 2010-01-12 | 2015-11-10 | Dance Biopharm Inc. | Preservative free insulin formulations and systems and methods for aerosolizing |
US10842951B2 (en) | 2010-01-12 | 2020-11-24 | Aerami Therapeutics, Inc. | Liquid insulin formulations and methods relating thereto |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
AR091902A1 (es) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
CN116987172A (zh) | 2014-01-20 | 2023-11-03 | 韩美药品株式会社 | 长效胰岛素及其用途 |
CA2944138C (en) * | 2014-03-31 | 2023-06-20 | Hanmi Pharm. Co., Ltd. | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage |
AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
TWI684458B (zh) * | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物 |
US10894089B2 (en) | 2015-02-17 | 2021-01-19 | Hanmi Pharm. Co., Ltd. | Long-acting insulin or insulin analogue conjugate |
WO2016137569A1 (en) | 2015-02-25 | 2016-09-01 | Dance Biopharm, Inc. | Liquid insulin formulations and methods relating thereto |
AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
CN108136276B (zh) * | 2015-09-24 | 2023-02-28 | 韩美药品株式会社 | 通过使用免疫球蛋白片段的特异性位点进行连接的蛋白质复合物 |
CN105597087B (zh) * | 2016-01-06 | 2019-04-26 | 山东新时代药业有限公司 | 一种甘精胰岛素注射液及其制备方法 |
GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
TWI774694B (zh) | 2016-09-23 | 2022-08-21 | 南韓商韓美藥品股份有限公司 | 具有降低對胰島素受體之親和力之胰島素類似物及其用途 |
CA3054899A1 (en) * | 2017-03-23 | 2018-09-27 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
CN111406073A (zh) * | 2017-09-29 | 2020-07-10 | 韩美药品株式会社 | 具有提高功效的持久性蛋白质缀合物 |
JP2022542301A (ja) * | 2019-07-31 | 2022-09-30 | イーライ リリー アンド カンパニー | リラキシン類似体およびその使用方法 |
AR127619A1 (es) | 2021-11-15 | 2024-02-14 | Lilly Co Eli | FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
US20020019352A1 (en) | 1997-04-17 | 2002-02-14 | David N. Brems | Stable, active, human ob protein compositions and methods |
US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
EP1355942B1 (en) * | 2000-12-07 | 2008-08-27 | Eli Lilly And Company | Glp-1 fusion proteins |
US20060183197A1 (en) | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
US6737401B2 (en) * | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
PT3417875T (pt) * | 2003-02-10 | 2020-08-24 | Biogen Ma Inc | Formulação de imunoglobulinas e método de preparação das mesmas |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
KR101135244B1 (ko) * | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
US8263084B2 (en) * | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
PT2256134E (pt) | 2003-11-13 | 2014-03-05 | Hanmi Science Co Ltd | Fragmento fc de igg para um veículo de fármaco e método para a preparação do mesmo |
US20080207505A1 (en) | 2005-01-12 | 2008-08-28 | James Kenneth D | Bna Conjugates and Methods of Use |
KR20090113340A (ko) * | 2007-03-22 | 2009-10-29 | 임클론 엘엘씨 | 안정한 항체 제제 |
EA201070121A1 (ru) | 2007-07-10 | 2010-06-30 | Эли Лилли Энд Компани | Лекарственная форма, содержащая слитый белок glp-1-fc |
WO2011041003A2 (en) * | 2009-06-22 | 2011-04-07 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
WO2011090306A2 (en) * | 2010-01-19 | 2011-07-28 | Hanmi Holdings Co., Ltd | Liquid formulations for long-acting erythropoietin conjugate |
AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
KR101324828B1 (ko) | 2010-06-08 | 2013-11-01 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체 |
KR101330868B1 (ko) | 2010-06-08 | 2013-11-18 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체 |
KR101337797B1 (ko) | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
KR101303388B1 (ko) * | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
-
2013
- 2013-07-24 AR ARP130102651A patent/AR091902A1/es unknown
- 2013-07-25 TW TW102126620A patent/TWI605824B/zh not_active IP Right Cessation
- 2013-07-25 CN CN201380039653.4A patent/CN104519871B/zh active Active
- 2013-07-25 MX MX2015000988A patent/MX369201B/es active IP Right Grant
- 2013-07-25 WO PCT/KR2013/006673 patent/WO2014017847A1/en active Application Filing
- 2013-07-25 DK DK13822348.2T patent/DK2877157T3/en active
- 2013-07-25 PL PL13822348T patent/PL2877157T3/pl unknown
- 2013-07-25 TR TR2019/03661T patent/TR201903661T4/tr unknown
- 2013-07-25 ES ES13822348T patent/ES2715326T3/es active Active
- 2013-07-25 AU AU2013293718A patent/AU2013293718B2/en active Active
- 2013-07-25 CA CA2879976A patent/CA2879976C/en active Active
- 2013-07-25 KR KR1020130087909A patent/KR102088856B1/ko active IP Right Grant
- 2013-07-25 EP EP13822348.2A patent/EP2877157B1/en active Active
- 2013-07-25 JP JP2015524184A patent/JP6385925B2/ja active Active
- 2013-07-25 US US14/415,206 patent/US10987424B2/en active Active
- 2013-07-25 TW TW106135078A patent/TW201803587A/zh unknown
- 2013-07-25 BR BR112015001457-7A patent/BR112015001457B1/pt active IP Right Grant
- 2013-07-25 PT PT13822348T patent/PT2877157T/pt unknown
- 2013-07-25 HU HUE13822348A patent/HUE042246T2/hu unknown
- 2013-07-25 RU RU2015104495A patent/RU2670270C2/ru active
-
2015
- 2015-07-07 HK HK15106482.5A patent/HK1207816A1/xx unknown
-
2018
- 2018-04-18 JP JP2018079838A patent/JP6682570B2/ja active Active
-
2019
- 2019-03-12 CY CY20191100288T patent/CY1121356T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX369201B (es) | Formulación líquida de un conjugado de insulina de acción prolongada. | |
MX369479B (es) | Formulación líquida de un cunjugado de péptido insulinotropico de acción prolongada. | |
MX2015001217A (es) | Formulacion liquida de insulina de accion prolongada y de peptido insulinotropico. | |
AU2017279583B2 (en) | Liquid Formulation Of Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment | |
PH12014502460A1 (en) | Lyophilised and aqueos anti-cd40 antibody formulations | |
WO2012008779A3 (en) | A liquid formulation of long-acting human growth hormone conjugate | |
MX2013004595A (es) | Formulaciones liquidas de un conjugado de alfa interferon de accion prolongada. | |
WO2012076670A3 (en) | Antibody formulation | |
MY179818A (en) | Antibody formulation | |
PH12015502441A1 (en) | Anti-il-4/anti-il-13 bispecific antibody formulations | |
JP2012051891A5 (es) | ||
WO2011090305A3 (en) | Liquid formulations for long-acting g-csf conjugate | |
AR090583A1 (es) | Formulacion liquida de conjugados de la hormona de crecimiento humana de accion prolongada, altamente concentrada | |
TH162100A (th) | สูตรตำรับรูปแบบของเหลวของโปรตีนคอนจูเกต (Protein Conjugate) ที่ประกอบด้วยออกซินโทโมดูลิน (Oxyntomodulin) และชิ้นส่วนของอิมมูโนโกลบูลิน (mmunoglobulin fragment) | |
TH125691B (th) | สูตรของแอนดี้บอดี้ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |